Zydus Lifesciences gets orphan drug designation for ZYIL1 in treatment of patients with CAPS

21 Mar 2023 Evaluate

Zydus Lifesciences has been granted ‘Orphan Drug Designation’ (ODD) by the United States Food and Drug Administration (USFDA) for ZYIL1, for treatment of patients with Cryopyrin Associated Periodic Syndrome (CAPS). The FDA's Office of Orphan Drug Products grants orphan status to support development of medicines for the treatment of rare diseases that affect fewer than 200,000 people in the United States.

ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates. In September 2022, Zydus had announced positive Phase 2 proof-of-concept (POC) study in CAPS patients, and publication of Phase 1 study results in Clinical Pharmacology in Drug Development, supporting the advancement of ZYIL1 into pivotal clinical trials in CAPS patients.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.

Zydus Lifesciences Share Price

937.80 2.80 (0.30%)
16-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1536.95
Dr. Reddys Lab 6038.00
Cipla 1384.30
Zydus Lifesciences 937.80
Lupin 1613.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.